A Double-blind, Intra-individual Comparison, Proof-of-concept Trial of Topical AC-203 in Patients With Inherited Epidermolysis Bullosa
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Proof of concept; Therapeutic Use
- Sponsors TWi Biotechnology
- 14 Mar 2018 Status changed from planning to not yet recruiting.
- 28 Feb 2018 New trial record
- 26 Feb 2018 According to a TWi Biotech media release, the Company has received approval from the Taiwan Food and Drug Administration (TFDA) to proceed this trial and expects the first patient to be enrolled in early Apr 2018.